​

Travere Therapeutics Ownership | Who Owns Travere Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Travere Therapeutics Ownership Summary

Travere Therapeutics is owned by 112.83% institutional investors, 0.74% insiders. Armistice capital is the largest institutional shareholder, holding 9.98% of TVTX shares. Delaware Small Cap Core I is the top mutual fund, with 4.42% of its assets in Travere Therapeutics shares.

TVTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTravere Therapeutics112.83%0.74%-13.58%
SectorHealthcare Stocks 486.50%11.08%-397.59%
IndustryBiotech Stocks 304.14%11.08%-215.23%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Armistice capital8.88M9.98%$131.36M
Blackrock7.64M9.86%$62.84M
Blackrock funding, inc. /de8.17M9.18%$120.90M
Vanguard group6.74M8.67%$117.45M
Macquarie group4.26M5.48%$74.20M
Janus henderson group4.06M5.22%$70.69M
State street3.51M4.53%$28.86M
Morgan stanley3.49M4.50%$28.69M
Adage capital partners gp2.78M3.13%$41.20M
Renaissance2.41M3.10%$41.97M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Superstring capital management lp276.47K4.84%$4.09M
Kynam capital management, lp1.54M2.46%$22.80M
Armistice capital8.88M2.27%$131.36M
Affinity asset advisors970.00K1.96%$14.36M
Exome asset management118.02K1.88%$2.11M
Eversept partners, lp1.32M1.79%$19.46M
Rock springs capital management lp1.91M1.76%$28.24M
Knott david m jr260.00K1.74%$3.85M
Birchview capital, lp103.00K1.51%$1.52M
Parkman healthcare partners827.06K1.41%$12.24M

Top Buyers

HolderShares% AssetsChange
Janus henderson group4.06M0.04%4.03M
Bnp paribas arbitrage, snc1.21M0.01%1.21M
Frazier life sciences management1.00M0.59%1.00M
Fmr1.12M0.00%972.60K
Perceptive advisors834.25K0.46%834.25K

Top Sellers

HolderShares% AssetsChange
State street3.51M0.00%-3.10M
Driehaus capital management---2.77M
Viking global investors lp---2.60M
Woodline partners lp2.11M0.25%-2.23M
Finepoint capital lp---1.78M

New Positions

HolderShares% AssetsChangeValue
Bnp paribas arbitrage, snc1.21M0.01%1.21M$21.07M
Frazier life sciences management1.00M0.59%1.00M$14.83M
Perceptive advisors834.25K0.46%834.25K$12.35M
Marshall wace, llp742.73K0.01%742.73K$10.99M
Tang capital management700.00K0.52%700.00K$10.36M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-14.00
Ifp advisors-17.00
Global retirement partners-19.00
Stephens consulting-20.00
Pnc financial services group-20.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025221-4.74%100,360,5602.40%1120.92%115-13.53%7120.34%
Mar 31, 202511-94.74%4,535,953-95.23%50.03%5-96.12%3-94.12%
Dec 31, 2024107-42.47%35,070,340-57.58%450.40%66-30.53%23-58.93%
Sep 30, 20241855.11%82,651,760-6.09%1060.82%96-6.80%5414.89%
Jun 30, 2024176-1.68%88,008,8780.38%1130.88%10310.75%47-7.84%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Delaware Small Cap Core I3.45M4.42%-21.39K
Macquarie Small Cap Core I3.61M4.07%-
Vanguard Total Stock Mkt Idx Inv2.79M3.13%-61.84K
Aviva Investors GlConvtAbsRet I USD Acc2.20M2.88%-229.35K
Vanguard US Total Market Shares ETF2.51M2.82%-
iShares Russell 2000 ETF2.08M2.33%-39.59K
Janus Henderson Global Life Sciences1.76M1.98%510.24K
Janus Henderson Global Life Sciences D1.76M1.98%173.21K
SPDR® S&P Biotech ETF1.50M1.69%37.07K
Janus Henderson Glb Life Scn I2 USD1.45M1.63%216.31K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 01, 2025Inrig Jula CHIEF MEDICAL OFFICERSell$11.94K
May 05, 2025Cline Christopher R. CHIEF FINANCIAL OFFICERSell$37.55K
May 05, 2025Dube Eric M CHIEF EXECUTIVE OFFICERSell$398.35K
May 05, 2025Heerma Peter CHIEF COMMERCIAL OFFICERSell$37.28K
May 05, 2025ROTE WILLIAM E. Chief Research OfficerSell$67.32K

Insider Transactions Trends

DateBuySell
2025 Q3-1
2025 Q2-6
2025 Q1-26
2024 Q4-4
2024 Q3-9

TVTX Ownership FAQ

Who Owns Travere Therapeutics?

Travere Therapeutics shareholders are primarily institutional investors at 112.83%, followed by 0.74% insiders and -13.57% retail investors. The average institutional ownership in Travere Therapeutics's industry, Biotech Stocks , is 304.14%, which Travere Therapeutics falls below.

Who owns the most shares of Travere Therapeutics?

Travere Therapeutics’s largest shareholders are Armistice capital (8.88M shares, 9.98%), Blackrock (7.64M shares, 9.86%), and Blackrock funding, inc. /de (8.17M shares, 9.18%). Together, they hold 29.03% of Travere Therapeutics’s total shares outstanding.

Does Blackrock own Travere Therapeutics?

Yes, BlackRock owns 9.86% of Travere Therapeutics, totaling 7.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.84M$. In the last quarter, BlackRock decreased its holdings by -152K shares, a -1.95% change.

Who is Travere Therapeutics’s biggest shareholder by percentage of total assets invested?

Superstring capital management lp is Travere Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.84% of its assets in 276.47K Travere Therapeutics shares, valued at 4.09M$.

Who is the top mutual fund holder of Travere Therapeutics shares?

Delaware Small Cap Core I is the top mutual fund holder of Travere Therapeutics shares, with 4.42% of its total shares outstanding invested in 3.45M Travere Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools